Shira Warszawski, Elya Dekel, Ivan Campeotto, Jennifer M Marshall, Katherine E Wright, Oliver Lyth, Orli Knop, Neta Regev-Rudzki, Matthew K Higgins, Simon J Draper, Jake Baum, Sarel J Fleishman
{"title":"设计一种以疟疾入侵蛋白 RH5 为靶标的拟基蛋白抑制剂。","authors":"Shira Warszawski, Elya Dekel, Ivan Campeotto, Jennifer M Marshall, Katherine E Wright, Oliver Lyth, Orli Knop, Neta Regev-Rudzki, Matthew K Higgins, Simon J Draper, Jake Baum, Sarel J Fleishman","doi":"10.1002/prot.25786","DOIUrl":null,"url":null,"abstract":"<p><p>Many human pathogens use host cell-surface receptors to attach and invade cells. Often, the host-pathogen interaction affinity is low, presenting opportunities to block invasion using a soluble, high-affinity mimic of the host protein. The Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) provides an exciting candidate for mimicry: it is highly conserved and its moderate affinity binding to the human receptor basigin (K<sub>D</sub> ≥1 μM) is an essential step in erythrocyte invasion by this malaria parasite. We used deep mutational scanning of a soluble fragment of human basigin to systematically characterize point mutations that enhance basigin affinity for RH5 and then used Rosetta to design a variant within the sequence space of affinity-enhancing mutations. The resulting seven-mutation design exhibited 1900-fold higher affinity (K<sub>D</sub> approximately 1 nM) for RH5 with a very slow binding off rate (0.23 h<sup>-1</sup> ) and reduced the effective Plasmodium growth-inhibitory concentration by at least 10-fold compared to human basigin. The design provides a favorable starting point for engineering on-rate improvements that are likely to be essential to reach therapeutically effective growth inhibition.</p>","PeriodicalId":39340,"journal":{"name":"NASSP Bulletin","volume":"39 1","pages":"187-195"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904230/pdf/","citationCount":"0","resultStr":"{\"title\":\"Design of a basigin-mimicking inhibitor targeting the malaria invasion protein RH5.\",\"authors\":\"Shira Warszawski, Elya Dekel, Ivan Campeotto, Jennifer M Marshall, Katherine E Wright, Oliver Lyth, Orli Knop, Neta Regev-Rudzki, Matthew K Higgins, Simon J Draper, Jake Baum, Sarel J Fleishman\",\"doi\":\"10.1002/prot.25786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Many human pathogens use host cell-surface receptors to attach and invade cells. Often, the host-pathogen interaction affinity is low, presenting opportunities to block invasion using a soluble, high-affinity mimic of the host protein. The Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) provides an exciting candidate for mimicry: it is highly conserved and its moderate affinity binding to the human receptor basigin (K<sub>D</sub> ≥1 μM) is an essential step in erythrocyte invasion by this malaria parasite. We used deep mutational scanning of a soluble fragment of human basigin to systematically characterize point mutations that enhance basigin affinity for RH5 and then used Rosetta to design a variant within the sequence space of affinity-enhancing mutations. The resulting seven-mutation design exhibited 1900-fold higher affinity (K<sub>D</sub> approximately 1 nM) for RH5 with a very slow binding off rate (0.23 h<sup>-1</sup> ) and reduced the effective Plasmodium growth-inhibitory concentration by at least 10-fold compared to human basigin. The design provides a favorable starting point for engineering on-rate improvements that are likely to be essential to reach therapeutically effective growth inhibition.</p>\",\"PeriodicalId\":39340,\"journal\":{\"name\":\"NASSP Bulletin\",\"volume\":\"39 1\",\"pages\":\"187-195\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904230/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NASSP Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/prot.25786\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/8/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Social Sciences\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NASSP Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/prot.25786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/8/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Social Sciences","Score":null,"Total":0}
Design of a basigin-mimicking inhibitor targeting the malaria invasion protein RH5.
Many human pathogens use host cell-surface receptors to attach and invade cells. Often, the host-pathogen interaction affinity is low, presenting opportunities to block invasion using a soluble, high-affinity mimic of the host protein. The Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) provides an exciting candidate for mimicry: it is highly conserved and its moderate affinity binding to the human receptor basigin (KD ≥1 μM) is an essential step in erythrocyte invasion by this malaria parasite. We used deep mutational scanning of a soluble fragment of human basigin to systematically characterize point mutations that enhance basigin affinity for RH5 and then used Rosetta to design a variant within the sequence space of affinity-enhancing mutations. The resulting seven-mutation design exhibited 1900-fold higher affinity (KD approximately 1 nM) for RH5 with a very slow binding off rate (0.23 h-1 ) and reduced the effective Plasmodium growth-inhibitory concentration by at least 10-fold compared to human basigin. The design provides a favorable starting point for engineering on-rate improvements that are likely to be essential to reach therapeutically effective growth inhibition.